Accelerate Diagnostics Inc - Asset Resilience Ratio
Accelerate Diagnostics Inc (AXDX) has an Asset Resilience Ratio of 4.20% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how Accelerate Diagnostics Inc's Asset Resilience Ratio has changed over time. Check AXDX strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Accelerate Diagnostics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Accelerate Diagnostics Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.20 Million | 4.2% |
| Total Liquid Assets | $1.20 Million | 4.20% |
Asset Resilience Insights
- Limited Liquidity: Accelerate Diagnostics Inc maintains only 4.20% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Accelerate Diagnostics Inc Industry Peers by Asset Resilience Ratio
Compare Accelerate Diagnostics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Xiangyu Medical Co. Ltd. A
SHG:688626 |
Medical Devices | 1.53% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Shenzhen Lifotronic Technology Co
SHG:688389 |
Medical Devices | 2.53% |
|
Shanghai Sanyou Medical Co Ltd
SHG:688085 |
Medical Devices | 7.69% |
|
Monogram Orthopaedics Inc. Common Stock
NASDAQ:MGRM |
Medical Devices | 0.18% |
|
T&R Biofab Co. Ltd
KQ:246710 |
Medical Devices | 0.12% |
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
Annual Asset Resilience Ratio for Accelerate Diagnostics Inc (2012–2024)
The table below shows the annual Asset Resilience Ratio data for Accelerate Diagnostics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.20% | $1.20 Million | $28.56 Million | +0.75pp |
| 2023-12-31 | 3.45% | $1.08 Million | $31.37 Million | -12.94pp |
| 2022-12-31 | 16.39% | $10.66 Million | $65.02 Million | -12.17pp |
| 2021-12-31 | 28.56% | $23.72 Million | $83.05 Million | -6.21pp |
| 2020-12-31 | 34.77% | $32.49 Million | $93.42 Million | -0.51pp |
| 2019-12-31 | 35.29% | $47.44 Million | $134.42 Million | -18.81pp |
| 2018-12-31 | 54.09% | $100.22 Million | $185.26 Million | -9.54pp |
| 2017-12-31 | 63.64% | $80.65 Million | $126.73 Million | -6.99pp |
| 2016-12-31 | 70.63% | $58.52 Million | $82.85 Million | +62.13pp |
| 2015-12-31 | 8.50% | $11.84 Million | $139.32 Million | -10.29pp |
| 2014-12-31 | 18.79% | $13.12 Million | $69.80 Million | -8.75pp |
| 2013-12-31 | 27.54% | $11.96 Million | $43.43 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $17.21 Million | -- |
About Accelerate Diagnostics Inc
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States and internationally. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing (AST) of pathogens associated with serious or health care-associated infections, including gram-po… Read more